$TERN
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Healthcare
Sector
Biotechnology
Industry
Amy L. Burroughs
CEO
59
Employees
$48.44
Current Price
$3.54B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 2 | $681,108.26 | 14,583 | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 2 | $681,108.26 | 14,583 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 2 | $681,108.26 | 14,583 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 5 | $1,252,687.34 | 29,166 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 10 | $6,564,072.55 | 170,409 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Mar 16, 2026 | Burroughs Amy L. Director | Sale | 11,813 | $46.57 | $550,080.61 | View Details |
| Mar 16, 2026 | Burroughs Amy L. Director | Sale | 2,770 | $47.30 | $131,027.65 | View Details |
| Feb 17, 2026 | Burroughs Amy L. Director | Sale | 8,159 | $39.22 | $319,963.34 | View Details |
| Feb 17, 2026 | Burroughs Amy L. Director | Sale | 4,083 | $39.80 | $162,501.36 | View Details |
| Feb 17, 2026 | Burroughs Amy L. Director | Sale | 2,341 | $38.07 | $89,114.38 | View Details |
| Jan 15, 2026 | Burroughs Amy L. Director | Sale | 61,228 | $37.02 | $2,266,372.79 | View Details |
| Jan 15, 2026 | Burroughs Amy L. Director | Sale | 7,521 | $37.53 | $282,230.04 | View Details |
| Jan 5, 2026 | Burroughs Amy L. Director | Sale | 71,339 | $38.10 | $2,718,229.92 | View Details |
| Jan 2, 2026 | Kuriakose Emil Chief Medical Officer | Sale | 955 | $38.36 | $36,632.46 | View Details |
| Jan 2, 2026 | Kuriakose Emil Chief Medical Officer | Sale | 200 | $39.60 | $7,920.00 | View Details |
10 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
EPS
Estimated-$0.29
ActualN/A
Revenue
EstimatedN/A
ActualN/A
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Past Earnings
Historical earnings results
EPS
Estimated-$0.29
ActualN/A
Revenue
EstimatedN/A
ActualN/A
3 more earnings records available โ create a free account to see 12 months of history